In agreement with the proposal by Ghasemi et al. [5], we believe that these MYCN amplified ependymomas should be recognized as a distinctive type of spinal cord ependymoma (SP-EPN-MYCN) with their unique molecular characteristics and aggressive clinical behavior. The gene discussed is MYCN; the disease is spinal cord ependymoma.